Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gabitril · 5 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Gabitril | DRUG | - |
| GABITRIL (tiagabine hydrochloride; CEP-6671) | DRUG | - |
Subjects who have completed 10 weeks of double-blind treatment and the subsequent taper period in 1 of the 3 previous double-blind studies (studies C6671/3030/AX/US, C6671/3031/AX/US, or C6671/3032/AX/US).
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2 | PHASE3 | DT120 |
| Vistagen Therapeutics, Inc. | VTGN | 3 | PHASE3 | Fasedienol |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | VQW-765 |
| AbbVie, Inc. | ABBV | 1 | PHASE2 | ABBV-932 |
| Psyence Biomedical Ltd. | PBM | 1 | PHASE2 | Psilocybin therapy |
Gabitril is a small molecule drug developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. It is being studied as a treatment for anxiety disorders, including generalized anxiety disorder. Gabitril is also known by the chemical name tiagabine hydrochloride and by the development code CEP-6671.
Gabitril is being evaluated for the treatment of generalized anxiety disorder in adults. Its clinical program includes Phase 3 trials in this indication, with studies enrolling adults aged 18 years and older. The trials were conducted in the United States and Canada and have been completed.
Gabitril is developed by Teva Pharmaceutical Industries Limited, which is listed under the ticker symbol TEVA. Teva is the sponsor of the clinical development program evaluating Gabitril in anxiety disorders, including generalized anxiety disorder.
Gabitril is in Phase 3 clinical development for anxiety disorders, including generalized anxiety disorder. The completed Phase 3 studies were randomized and double blind, and enrolled adults aged 18 years and older. Gabitril remains an investigational treatment in this development program.
Gabitril has been studied in completed Phase 3 trials, including NCT00236067, NCT00236054, NCT00236015, and NCT00233675. These trials evaluated Gabitril in adults with generalized anxiety disorder or anxiety disorder, with enrollment of 440 or 880 participants in the individual studies. The studies took place in the United States and Canada.
Yes, Gabitril is the brand name for tiagabine hydrochloride, which is also identified by the development code CEP-6671. These names refer to the same small molecule drug developed by Teva Pharmaceutical Industries Limited for anxiety disorders, including generalized anxiety disorder.